Drug Trial Radar · NCT05845814
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Jun 23, 2023
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated favezelimab/pembrolizumab plus EV and coformulated vibostolimab/pembrolizumab plus EV relative to pembrolizumab plus EV. There will be no comparison of coformulated favezelimab/pembrolizumab plus EV versus coformulated vibostolimab/pembrolizumab plus EV. If ORR and/or DRR are substantially better on coformulated favezelimab/pembrolizumab plus EV and/or coformulated vibostolimab/pembrolizumab plus EV compared with pembrolizumab plus EV, after evaluation of the totality of data, the sponsor might consider Part 2 (expansion) to further characterize the efficacy and safety of the treatment arms under study.
Conditions
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
Interventions
Coformulated favezelimab/pembrolizumabBiological
Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
Coformulated vibostolimab/pembrolizumabBiological
Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
EVCombination product
1.25 mg/kg IV infusion
PembrolizumabBiological
200 mg IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Objective Response Rate (ORR)Time frame: Up to ~4 years
- Part 1: Percentage of Participants experiencing an Adverse Event (AE)Time frame: Up to ~4 years
- Part 1: Percentage of Participants who Discontinue study interventions due to an AETime frame: Up to ~4 years
- Part 1: Percentage of Participants with Dose-limiting toxicities (DLT)Time frame: Up to 21 days
- Part 2: Progression Free Survival (PFS)Time frame: Up to ~4 years
Locations
47 sites in 12 countries. Site status is shown where the registry gives one.
Moores Cancer Center ( Site 3028)
La Jolla, California
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3045)
Orange, California
UCSF Medical Center at Mission Bay ( Site 3044)
San Francisco, California
Anschutz Cancer Pavilion ( Site 3017)
Aurora, Colorado
Emory University School of Medicine ( Site 3043)
Atlanta, Georgia
Indiana University Melvin and Bren Simon Cancer Center ( Site 3011)
Indianapolis, Indiana
Dana-Farber Cancer Institute ( Site 3047)
Boston, Massachusetts
Siteman Cancer Center ( Site 3038)
St Louis, Missouri
Icahn School of Medicine at Mount Sinai ( Site 3018)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 3031)
New York, New York
Duke Cancer Institute ( Site 3027)
Durham, North Carolina
Cleveland Clinic-Taussig Cancer Center ( Site 3036)
Cleveland, Ohio
UPMC Hillman Cancer Center ( Site 3014)
Pittsburgh, Pennsylvania
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 3041)
Salt Lake City, Utah
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 3951)
Brisbane, Queensland, Australia
Austin Health-Cancer Clinical Trials Centre ( Site 3950)
Heidelberg, Victoria, Australia
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 3105)
Ottawa, Ontario, Canada
Sunnybrook Research Institute - Odette Cancer Centre ( Site 3108)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 3106)
Toronto, Ontario, Canada
Bradford Hill Norte ( Site 3152)
Antofagasta, Chile
FALP-UIDO ( Site 3151)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 3155)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 3158)
Viña del Mar, Valparaiso, Chile
Hôpital Européen Georges Pompidou ( Site 3605)
Paris, France
CHU de Bordeaux Hop St ANDRE ( Site 3607)
Bordeaux, Aquitaine, France
Centre Georges François Leclerc-Centre de recherche clinique ( Site 3608)
Dijon, Cote-d Or, France
Oncopole Claudius Regaud ( Site 3610)
Toulouse, Haute-Garonne, France
centre hospitalier lyon sud ( Site 3606)
Pierre-Bénite, Rhone, France
Rambam Health Care Campus-Oncology Division ( Site 3501)
Haifa, Israel
Rabin Medical Center-Oncology ( Site 3504)
Petah Tikva, Israel
Sheba Medical Center-ONCOLOGY ( Site 3503)
Ramat Gan, Israel
Ospedale San Raffaele-Oncologia Medica ( Site 3403)
Milan, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3406)
Naples, Campania, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3405)
Milan, Lombardy, Italy
Maastricht UMC+ ( Site 3304)
Maastricht, Limburg, Netherlands
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 3302)
Amsterdam, North Holland, Netherlands
Erasmus Medisch Centrum-Medical Oncology ( Site 3303)
Rotterdam, South Holland, Netherlands
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3903)
Seoul, South Korea
Asan Medical Center-Department of Oncology ( Site 3901)
Seoul, South Korea
Samsung Medical Center ( Site 3902)
Seoul, South Korea
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.